Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 261,509,584
  • Shares Outstanding, K 5,952,870
  • Annual Sales, $ 52,546 M
  • Annual Income, $ 21,308 M
  • 36-Month Beta 0.96
  • Price/Sales 4.99
  • Price/Cash Flow 11.75
  • Price/Book 3.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.75
  • Number of Estimates 6
  • High Estimate 0.78
  • Low Estimate 0.72
  • Prior Year 0.67
  • Growth Rate Est. (year over year) +11.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.09 +6.57%
on 08/31/18
44.46 -1.50%
on 09/24/18
+1.39 (+3.28%)
since 08/24/18
3-Month
36.00 +21.64%
on 07/02/18
44.46 -1.50%
on 09/24/18
+7.41 (+20.37%)
since 06/25/18
52-Week
33.20 +31.90%
on 02/09/18
44.46 -1.50%
on 09/24/18
+8.28 (+23.32%)
since 09/25/17

Most Recent Stories

More News
AstraZeneca's Imfinzi Gets EU Nod for Early-Stage Lung Cancer

AstraZeneca's (AZN) PD-L1 inhibitor Imfinzi gets approval in EU for an early-stage lung cancer indication.

AZN : 38.69 (+2.22%)
MRK : 70.65 (-0.18%)
PFE : 43.79 (-0.32%)
BMY : 61.82 (+0.37%)
Factors of Influence in 2018, Key Indicators and Opportunity within Dorchester Minerals, Teladoc, Pfizer, Intercontinental Exchange, General Electric, and Prospect Capital -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorchester Minerals, L.P. (NASDAQ:DMLP),...

TDOC : 80.75 (+2.87%)
PSEC : 7.40 (+0.14%)
ICE : 76.37 (-1.62%)
DMLP : 20.40 (+4.35%)
PFE : 43.79 (-0.32%)
GE : 11.27 (-4.00%)
Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals

Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative technology-based therapeutic products that address unmet patient needs, today announced the acquisition of NextWave...

PFE : 43.79 (-0.32%)
The New York Academy of Medicine to Host Special Conversation with Four Former U.S. Surgeons General on October 15

On October 15 at 6:00pm, The New York Academy of Medicine will host an intimate conversation with four former U.S. Surgeons General: Antonia Novello, MD, MPH, DrPH, Joycelyn Elders, MD, MS, David Satcher,...

PFE : 43.79 (-0.32%)
Immutep Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany, and Pfizer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company") is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany...

IMMP : 3.62 (+12.42%)
PFE : 43.79 (-0.32%)
Global Moyamoya Market Report 2018 : Data Includes Research & Development News, Patient Uprising Explored Through 2018-2023

VRX.TO : 30.80 (-3.33%)
SIEGY : 65.3750 (+0.26%)
BSX : 38.61 (+0.55%)
MRK : 70.65 (-0.18%)
NVS : 85.90 (+0.72%)
MDT : 99.00 (+0.14%)
ESALF : 95.7500 (+3.23%)
GSK : 40.36 (+0.40%)
PFE : 43.79 (-0.32%)
Pfizer (PFE) Gains As Market Dips: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $44.06, marking a +0.71% move from the previous day.

PFE : 43.79 (-0.32%)
Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status

Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.

ABBV : 93.78 (+0.39%)
RHHBY : 30.5500 (+1.26%)
AMGN : 206.46 (-0.36%)
PFE : 43.79 (-0.32%)
Dow 30 Stock Roundup: JPMorgan Ups Dividend, Disney's ESPN+ Hits 1M Paid Subscribers

The index made strong gains this week as investors shrugged off trade tensions.

MSFT : 114.45 (-0.19%)
C : 73.51 (-0.45%)
BAC : 30.67 (-0.23%)
MA : 222.12 (+0.35%)
JPM : 116.39 (-0.28%)
V : 149.58 (+0.32%)
GS : 232.50 (-0.17%)
PFE : 43.79 (-0.32%)
DIS : 113.63 (+0.76%)
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share

Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.

LLY : 105.70 (+0.10%)
ZTS : 90.26 (+0.68%)
NVS : 85.90 (+0.72%)
PFE : 43.79 (-0.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade PFE with:

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

2nd Resistance Point 44.48
1st Resistance Point 44.13
Last Price 43.79
1st Support Level 43.60
2nd Support Level 43.42

See More

52-Week High 44.46
Last Price 43.79
Fibonacci 61.8% 40.16
Fibonacci 50% 38.83
Fibonacci 38.2% 37.50
52-Week Low 33.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar